Interpace Biosciences, Inc. (OTCMKTS:IDXG) Shares Shorted: Short Interest Up 550.0% in October

Interpace Biosciences, Inc. (OTCMKTS:IDXG) was the recipient of a large increase in short interest in October. As of October 30th, there was short interest totaling 13 shares, an increase of 550.0% from the October 15th total of 2 shares. Based on an average trading volume of 4,223 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the company’s shares are sold short.

Interpace Biosciences Price Performance

IDXG stock opened at $7.00 on Wednesday. Interpace Biosciences has a 1 year low of $4.95 and a 1 year high of $7.45. The company’s 50-day moving average is $6.59 and its 200-day moving average is $8.03.

Interpace Biosciences (OTCMKTS:IDXG) last announced its quarterly earnings results on Monday, August 10th. The business services provider reported $0.05 earnings per share for the quarter. Interpace Biosciences had a net margin of 67.64% and a return on equity of 145.40%. The business had revenue of $9.13 million for the quarter.

About Interpace Biosciences

Interpace Biosciences, Inc. is a molecular diagnostics company focused on improving the diagnosis and management of cancer and other complex diseases. The company develops and commercializes molecular tests that help physicians evaluate disease risk, guide treatment decisions and reduce uncertainty associated with conventional diagnostic procedures. Its portfolio has included tests for thyroid, pancreatic and gastroesophageal conditions. ThyGeNEXT and ThyraMIR are designed to help evaluate indeterminate thyroid nodules, while PancraGEN supports risk assessment for pancreatic cysts.